Intellia Therapeutics, Inc. (NTLA)
13.07
+0.47
(+3.73%)
USD |
NASDAQ |
Oct 09, 16:00
13.08
+0.01
(+0.08%)
After-Hours: 20:00
Intellia Therapeutics Cash from Operations (Quarterly) : -83.11M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -83.11M |
| March 31, 2026 | -117.35M |
| December 31, 2025 | -69.28M |
| September 30, 2025 | -76.90M |
| June 30, 2025 | -99.62M |
| March 31, 2025 | -148.93M |
| December 31, 2024 | -85.20M |
| September 30, 2024 | -84.84M |
| June 30, 2024 | -58.19M |
| March 31, 2024 | -120.66M |
| December 31, 2023 | -93.05M |
| September 30, 2023 | -101.38M |
| June 30, 2023 | -90.32M |
| March 31, 2023 | -109.33M |
| December 31, 2022 | -89.87M |
| September 30, 2022 | -78.53M |
| June 30, 2022 | -85.09M |
| March 31, 2022 | -79.80M |
| December 31, 2021 | -54.65M |
| September 30, 2021 | -65.02M |
| June 30, 2021 | -52.98M |
| Date | Value |
|---|---|
| March 31, 2021 | -52.38M |
| December 31, 2020 | -40.23M |
| September 30, 2020 | -28.56M |
| June 30, 2020 | 57.42M |
| March 31, 2020 | -38.54M |
| December 31, 2019 | -28.66M |
| September 30, 2019 | -25.45M |
| June 30, 2019 | -27.68M |
| March 31, 2019 | -21.45M |
| December 31, 2018 | -8.538M |
| September 30, 2018 | -12.45M |
| June 30, 2018 | -22.50M |
| March 31, 2018 | -17.77M |
| December 31, 2017 | -21.31M |
| September 30, 2017 | -16.89M |
| June 30, 2017 | -15.68M |
| March 31, 2017 | -11.40M |
| December 31, 2016 | -14.41M |
| September 30, 2016 | -7.61M |
| June 30, 2016 | 67.55M |
| March 31, 2016 | -9.421M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Twist Bioscience Corp. | 1.115M |
| Beam Therapeutics, Inc. | -66.10M |
| Prime Medicine, Inc. | -41.05M |
| Moderna, Inc. | -526.00M |
| Q32 Bio, Inc. | -3.075M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -141.57M |
| Cash from Financing (Quarterly) | 196.12M |
| Free Cash Flow | -348.69M |
| Free Cash Flow Per Share (Quarterly) | -0.6362 |
| Free Cash Flow to Equity (Quarterly) | -77.84M |
| Free Cash Flow to Firm (Quarterly) | -84.92M |
| Free Cash Flow Yield | -22.32% |